Wulf Palinski

Active 1985–2021

71
Papers
23,869
Citations
69
h-index
71
i10-index

Citations

Citations per year for Wulf Palinski1968: 1 citations1984: 1 citations1989: 17 citations1990: 50 citations1991: 96 citations1992: 87 citations1993: 118 citations1994: 126 citations1995: 205 citations1996: 189 citations1997: 233 citations1998: 282 citations1999: 357 citations2000: 382 citations2001: 429 citations2002: 391 citations2003: 426 citations2004: 449 citations2005: 378 citations2006: 432 citations2007: 270 citations2008: 317 citations2009: 274 citations2010: 200 citations2011: 197 citations2012: 157 citations2013: 133 citations2014: 132 citations2015: 94 citations2016: 121 citations2017: 89 citations2018: 131 citations2019: 253 citations2020: 266 citations2021: 238 citations2022: 162 citations2023: 114 citations2024: 170 citations2025: 68 citations1969–1983: no citations, so these years are not shown1985–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,402 citing papers, 36.3% of this breakdownUnited Kingdom: 409 citing papers, 6.2% of this breakdownJapan: 331 citing papers, 5% of this breakdownGermany: 317 citing papers, 4.8% of this breakdownChina: 294 citing papers, 4.4% of this breakdownItaly: 261 citing papers, 3.9% of this breakdownFrance: 245 citing papers, 3.7% of this breakdownSweden: 206 citing papers, 3.1% of this breakdownCanada: 196 citing papers, 3% of this breakdownNetherlands: 183 citing papers, 2.8% of this breakdownAustria: 182 citing papers, 2.8% of this breakdownAustralia: 153 citing papers, 2.3% of this breakdown
0%36.3%Other 21.7%

Fields

  • Medicine46.6%
  • Biochemistry, Genetics and Molecular Biology25.3%
  • Immunology and Microbiology21.8%
  • Nursing2.1%
  • Neuroscience1.3%
  • Agricultural and Biological Sciences0.6%
  • Other2.3%

Topics

  • Atherosclerosis and Cardiovascular Diseases9.6%
  • Antioxidant Activity and Oxidative Stress6.4%
  • Peroxisome Proliferator-Activated Receptors4.4%
  • Adipokines, Inflammation, and Metabolic Diseases3.8%
  • Cholesterol and Lipid Metabolism3%
  • Lipoproteins and Cardiovascular Health2.5%
  • Other70.3%

Coauthors

All papers

Open in search
  1. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL

    Authors: , , , , , , , , , - Nature Medicine 2003 cited by 735

  2. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study

    Authors: , , , , , - The Lancet 1999 cited by 648

  3. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions.

    Authors: , , , , , , - Journal of Clinical Investigation 1997 cited by 1,007

  4. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy.

    Authors: , , - 1991 cited by 487

  5. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ

    Authors: , , , , , , , , , , , - Journal of Clinical Investigation 2004 cited by 566

  6. Effect of Maternal Cardiovascular Conditions and Risk Factors on Offspring Cardiovascular Disease

    Authors: - Circulation 2014 cited by 132

  7. Low density lipoprotein undergoes oxidative modification in vivo.

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1989 cited by 1,526

  8. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity

    Authors: , , , , , , - Journal of Clinical Investigation 2000 cited by 670

  9. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid–protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins

    Authors: , , , , , , , , , , , - Journal of Clinical Investigation 1999 cited by 557

  10. Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo

    Authors: , , , , , , , , , , , , - Journal of Biological Chemistry 1997 cited by 752

  11. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

    Authors: , , , , , , - Journal of Clinical Investigation 1996 cited by 557

  12. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.

    Authors: , , , , , - Arteriosclerosis and Thrombosis A Journal of Vascular Biology 1994 cited by 548

  13. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis

    Authors: , , , , , , , , - Journal of Clinical Investigation 2004 cited by 411

  14. Scavenger Receptors, Oxidized LDL, and Atherosclerosis

    Authors: , , , , , , , , , , , , - Annals of the New York Academy of Sciences 2001 cited by 332

  15. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.

    Authors: , , , , , , , - Journal of Clinical Investigation 1989 cited by 1,892

  16. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.

    Authors: , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1995 cited by 596

  17. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol‐lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis

    Authors: , - The FASEB Journal 2002 cited by 267

  18. Autoantibody against oxidised LDL and progression of carotid atherosclerosis

    Authors: , , , , , , , , - The Lancet 1992 cited by 1,317

  19. Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

    Authors: , , , , , - Journal of Clinical Investigation 2000 cited by 841

  20. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1998 cited by 721

  21. Lysosome purinergic receptor P2X4 regulates neoangiogenesis induced by microvesicles from sarcoma patients

    Authors: , , , , , , , , , , , , , , , , - Cell Death and Disease 2021 cited by 34

  22. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice

    Authors: , , - Journal of Lipid Research 1995 cited by 516

  23. Human-Derived Anti-Oxidized LDL Autoantibody Blocks Uptake of Oxidized LDL by Macrophages and Localizes to Atherosclerotic Lesions In Vivo

    Authors: , , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2001 cited by 221

  24. Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice

    Authors: , , - Arteriosclerosis Thrombosis and Vascular Biology 2001 cited by 153